Researchers from Hospital Clínic and IDIBAPS have published a review on bipolar disorder in the prestigious journal The Lancet. It is an update on the latest developments in tackling this disease, of which a complete vision is offered. Researchers emphasize in the importance of a translational approach of bipolar disorder and underline the need to search for biomarkers for a better diagnosis and a personalized treatment. The article has been coordinated by Dr. Eduard Vieta, head of the unit and research group on Bipolar Disorder at Hospital Clinic and IDIBAPS, and Dr. Iria Grande, specialist at the same team.
Dr. Jordi Bruix, new Scientific Director of the Networked Biomedical Research Center for Hepatic and Digestive Diseases
Dr. Jordi Bruix, group leader of the Networked Biomedical Research Center for Hepatic and Digestive Diseases (CIBEREHD) at Hospital Clínic and IDIBAPS, has been appointed CIBEREHD Scientific Director on the CIBER Standing Committee (dependent on the Carlos III Health Institute) held this morning. Dr. Bruix succeeds Dr. Jaume Bosch, also from the Hospital Clinic of and the IDIBAPS, who occupied this position since 2006.
A study led by researchers from Hospital Clínic and IDIBAPS defines more precisely the risk of developing colon cancer in patients with serrated polyposis, a syndrome in which colorectal polyps have a characteristic gear morphology. In a study published in the journal Gut, researchers have confirmed that this syndrome predisposes to colon cancer but with a lower risk than the previously published. Dr. Francesc Balaguer, head of the High Risk Colorectal Cancer Unit at Hospital Clínic of Barcelona and researcher at the Gastrointestinal and pancreatic oncology IDIBAPS team, has coordinated this study. The first author of the paper is Dr. Sabela Carballal, specialist at the Gastroenterology Department at Hospital Clinic.
The Translational Reserarch in Hepatic Oncology IDIBAPS group, led by Dr. Josep M. Llovet, in collaboration with Dr. Roser Pinyol and 8 more researchers, participates in a European project to identify the molecular mechanisms that have a direct impact on the development of hepatocellular carcinoma (HCC). The HEP-CAR project will evaluate the role of these mechanisms in different liver diseases leading to HCC -the infection by hepatitis B and C, overweight or alcohol-. This research initiative, coordinated by the University of Freiburg and in which ten European academic centers are involved, is part of Horizon 2020, the European Comission framework programme for research and innovation, and it is endowed with a budget of 5.7 million euros, one of them corresponding to IDIBAPS.
Researchers from the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and the Hospital Clínic of Barcelona, in collaboration with qGenomics, have developed a DNA chip, or array, to analyze the genome and identify genetic abnormalities in chronic lymphocytic leukemia. This chip allows overcoming the limitations for the detection of changes of the current techniques, such as fluorescent in situ hybridization (FISH), and can be used for a more accurate diagnosis of the disease.
A study published in the New England Journal of Medicine (NEJM) shows that the combination of two drugs (ambrisentan and tadalafil) is more effective than the use of one of these agents to treat pulmonary arterial hypertension. The combination therapy improves very significantly the outcome of patients with this disease and reduces by 50% the risk of clinical failure. Dr. Joan Albert Barberà, pulmonologist at Hospital Clínic and head of the IDIBAPS team Physiopathological mechanisms of respiratory illnesses is one of the authors of this study and coordinator of the trial in Spain.